Novartis completes divestiture of influenza vaccines business to CSL Limited for USD 275 million
(Thomson Reuters ONE) -
Novartis International AG /
Novartis completes divestiture of influenza vaccines business to CSL Limited for
USD 275 million
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* CSL Limited acquired influenza vaccines business of Novartis, including
influenza vaccines development pipeline
Basel, Switzerland, August 3, 2015 - Novartis today announced that it has
completed effective July 31, 2015 the divestiture of its influenza vaccine unit
to CSL Limited.
This marks the end of a series of transactions previously announced and
completed,that are focusing Novartis on its three leading businesses of global
scale - pharmaceuticals, generics and eye care.
Since April 2014, the influenza vaccines unit results have been reported under
Discontinuing Operations in the Novartis consolidated financial statements.
Disclaimer
Closing in certain jurisdictions is subject to statutory employee consultation.
The foregoing release contains forward-looking statements that can be identified
by words such as "pipeline," "are focusing," or similar terms, or by express or
implied discussions regarding any potential strategic benefits, synergies or
opportunities as a result of the announced transactions. You should not place
undue reliance on these statements. Such forward-looking statements are based on
the current beliefs and expectations of management regarding future events, and
are subject to significant known and unknown risks and uncertainties. Should one
or more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results may vary materially from those set
forth in the forward-looking statements. There can be no guarantee that Novartis
will be able to realize any of the potential strategic benefits, synergies or
opportunities as a result of the transactions. Neither can there be any
guarantee that Novartis will achieve any particular financial results in the
future. In particular, management's expectations could be affected by, among
other things, the uncertainties inherent in research and development, including
unexpected clinical trial results and additional analysis of existing data, and
unexpected safety data; unexpected regulatory actions or delays or government
regulation generally; the potential that the strategic benefits, synergies or
opportunities expected from the transactions may not be realized or may take
longer to realize than expected; the Company's ability to obtain or maintain
proprietary intellectual property protection; global trends toward health care
cost containment, including ongoing pricing pressures; general economic and
industry conditions, and other risks and factors referred to in Novartis AG's
current Form 20-F on file with the US Securities and Exchange Commission.
Novartis is providing the information in this press release as of this date and
does not undertake any obligation to update any forward-looking statements
contained in this press release as a result of new information, future events or
otherwise.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
eye care and cost-saving generic pharmaceuticals. Novartis is the only global
company with leading positions in these areas. In 2014, the Group achieved net
sales of USD 58.0 billion, while R&D throughout the Group amounted to
approximately USD 9.9 billion (USD 9.6 billion excluding impairment and
amortization charges). Novartis Group companies employ approximately 120,000
full-time-equivalent associates. Novartis products are available in more than
180 countries around the world. For more information, please visit
http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis.
Novartis Media Relations
Central media line: +41 61 324 2200
Eric Althoff Elizabeth Power
Novartis Global Media Relations Novartis Global Media Relations
+41 61 324 7999 (direct) +1 212 830 2466
+41 79 593 4202 (mobile) +1 617 583 3015
eric.althoff(at)novartis.com elizabeth.power(at)novartis.com
e-mail: media.relations(at)novartis.com
For Novartis multimedia content, please visit: www.thenewsmarket.com/Novartis
For questions about the site or required registration, please contact:
journalisthelp(at)thenewsmarket.com.
Novartis Investor Relations
Central phone: +41 61 324 7944
Samir Shah +41 61 324 7944 North America:
Pierre-Michel Bringer +41 61 324 1065 Richard Pulik +1 212 830 2448
Thomas Hungerbuehler +41 61 324 8425 Sloan Pavsner +1 212 830 2417
Isabella Zinck +41 61 324 7188
e-mail: investor.relations(at)novartis.com e-mail:
investor.relations(at)novartis.com
Media release (PDF):
http://hugin.info/134323/R/1943007/703228.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novartis International AG via GlobeNewswire
[HUG#1943007]
Unternehmensinformation / Kurzprofil:
Datum: 03.08.2015 - 00:30 Uhr
Sprache: Deutsch
News-ID 410929
Anzahl Zeichen: 6359
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 211 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novartis completes divestiture of influenza vaccines business to CSL Limited for USD 275 million"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
